How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,258 results for

adhd Methylphenidate

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

361. Attention Deficit Hyperactivity Disorder (Treatment)

=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTEyNjMzLXRyZWF0bWVudA== processing > Pediatric Attention Deficit Hyperactivity Disorder (ADHD) Treatment & Management Updated: Nov 20, 2018 Author: Maggie A Wilkes, MD; Chief Editor: Caroly Pataki, MD Share Email Print Feedback Close Sections Sections Pediatric Attention Deficit Hyperactivity Disorder (ADHD) Treatment Medical Care The first line of treatment for ADHD in children and adolescents is the use of stimulant medications, such as methylphenidate agents and amphetamine/mixed amphetamine salts agents (...) : Psychological Corp; 1996:5-6. Daley D, van der Oord S, Ferrin M, et al, for the European ADHD Guidelines Group. Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains. J Am Acad Child Adolesc Psychiatry . 2014 Aug. 53(8):835-847.e5. . Brauser D. Behavioral interventions effective for ADHD. Medscape Medical News . July 31, 2014. . Spinelli S, Joel S, Nelson TE, Vasa RA, Pekar JJ, Mostofsky SH. Different neural

2014 eMedicine Pediatrics

362. Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder

is to measure the effect of adult ADHD and methylphenidate on cerebral perfusion. This will be done through applying a novel arterial spin labelling MRI-technique on the participants in the fMRI arm of the study. Condition or disease Intervention/treatment Phase Attention Deficit-Hyperactivity Disorder Drug: Ritalin Drug: Placebo Phase 4 Detailed Description: The immediate scientific goal of this trial is to investigate the cognitive- and brain-mechanisms underlying Decision Making (DM) and instrumental (...) Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter

2013 Clinical Trials

363. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Full Text available with Trip Pro

European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. This study evaluated the efficacy and safety of lisdexamfetamine dimesylate (LDX) compared with placebo in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) in Europe. Osmotic-release oral system methylphenidate (OROS-MPH) was included as a reference arm. Patients (6-17 years old) with a baseline ADHD Rating Scale version IV (...) (ADHD-RS-IV) total score ≥ 28 were randomized (1:1:1) to dose-optimized LDX (30, 50, or 70 mg/day), OROS-MPH (18, 36, or 54 mg/day) or placebo for 7 weeks. Primary and key secondary efficacy measures were the investigator-rated ADHD-RS-IV and the Clinical Global Impressions-Improvement (CGI-I) rating, respectively. Safety assessments included treatment-emergent adverse events (TEAEs), electrocardiograms, and vital signs. Of 336 patients randomized, 196 completed the study. The difference between LDX

2013 European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology Controlled trial quality: uncertain

364. Commentary: Filling out the evidence base for treatment of attention-deficit hyperactivity disorder symptoms in children with intellectual and developmental disability: conclusions for clinicians - a response to Simonoff et al. (2013). Full Text available with Trip Pro

Commentary: Filling out the evidence base for treatment of attention-deficit hyperactivity disorder symptoms in children with intellectual and developmental disability: conclusions for clinicians - a response to Simonoff et al. (2013). This randomized clinical trial of methylphenidate in children with intellectual disability (ID) by Simonoff et al. (2013) advances the field in several ways useful to clinicians. The three-figure widely representative sample more definitively confirms findings

2013 Journal of Child Psychology and Psychiatry Controlled trial quality: uncertain

365. Rapid visual information processing as a cognitive endophenotype of attention deficit hyperactivity disorder. (Abstract)

Rapid visual information processing as a cognitive endophenotype of attention deficit hyperactivity disorder. Deficits in sustained attention and reaction time are core features of attention deficit hyperactivity disorder (ADHD). However, little is known about attention performance in unaffected siblings. Hence, we examined sustained attention and reaction time in youths with ADHD, unaffected siblings and controls to test whether impaired performance in attention tasks can be a potential (...) used for data analysis.Compared with the controls, probands with ADHD and unaffected siblings had significantly higher total misses, lower probability of hits in the RVP task and probands with ADHD performed worse in the RTI and MTS tasks after controlling for sex, age, co-morbidity, parental educational levels and IQ. The duration of methylphenidate use and IQ but not psychiatric co-morbidity or current use of methylphenidate were associated with deficits in sustained attention in probands

2013 Psychological Medicine

366. Association of childhood attention-deficit/hyperactivity disorder with atopic diseases and skin infections? A matched case-control study using the General Practice Research Database. (Abstract)

Association of childhood attention-deficit/hyperactivity disorder with atopic diseases and skin infections? A matched case-control study using the General Practice Research Database. Data to support the hypothesis of a relationship between attention-deficit/hyperactivity disorder (ADHD) and allergies are conflicting.To assess whether children with ADHD are more likely to have a history of atopic disorders, skin infections, and medical prescriptions than children without ADHD.We conducted (...) a nested case-control study among boys using the UK General Practice Research Database (GPRD). Cases were defined as children with first-time diagnosis of ADHD who were treated with methylphenidate. Four controls who had neither ADHD nor ADHD drug prescriptions in their medical records were matched to each case on age and general practice.We identified 884 boys with a first-time diagnosis of drug-treated ADHD and 3,536 controls. The independent odds ratios adjusted for age and presence of low birth

2013 Asthma & Immunology

367. No significant association between the alpha-2A-adrenergic receptor gene and treatment response in combined or inattentive subtypes of attention-deficit hyperactivity disorder. Full Text available with Trip Pro

No significant association between the alpha-2A-adrenergic receptor gene and treatment response in combined or inattentive subtypes of attention-deficit hyperactivity disorder. Given the shortage of pharmacogenetic studies on treatment response according to subtype of attention-deficit hyperactivity disorder (ADHD), we investigated the associations between the MspI and DraI polymorphisms of the alpha-2 A-adrenergic receptor gene (ADRA2A) and treatment response to methylphenidate according (...) to subtype of ADHD.We enrolled 115 medication-naïve children with ADHD into an open label 8-week trial of methylphenidate. The participants were genotyped and evaluated using the Clinical -Global Impression (CGI), ADHD rating scale, and Continuous Performance Test (CPT) pre- and post-treatment.There was no statistically significant association between the MspI or DraI genotypes and the relative frequency of CGI-improvement (CGI-I) 1 or 2 status among any of the groups (all types of ADHD, ADHD-C, or ADHD

2013 Pharmacopsychiatry

368. Gene-environment Interactions and Brain Functional Connectivity in Attention Deficit Hyperactivity Disorder

Numbers: 2010-0002283 First Posted: July 31, 2013 Results First Posted: December 4, 2014 Last Update Posted: December 4, 2014 Last Verified: November 2014 Keywords provided by Jae-Won Kim, Seoul National University: ADHD ADRA2A Methylphenidate Response Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders (...) predictors of treatment response associated with NE system genes in ADHD. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: Methylphenidate Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 83 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Basic Science Official Title: Gene-environment Interactions and Brain Functional

2013 Clinical Trials

369. [Assessment of healthcare status and therapeutic recommendations concerning attention deficit hyperactivity disorder]

[Assessment of healthcare status and therapeutic recommendations concerning attention deficit hyperactivity disorder] Evaluacion de la situacion asistencial y recomendaciones terapeuticas en el trastorno por deficit de atencion e hiperactividad [Assessment of healthcare status and therapeutic recommendations concerning attention deficit hyperactivity disorder] Evaluacion de la situacion asistencial y recomendaciones terapeuticas en el trastorno por deficit de atencion e hiperactividad (...) [Assessment of healthcare status and therapeutic recommendations concerning attention deficit hyperactivity disorder] Lasa-Zulueta Alberto, Jorquera-Cuevas Cristina Citation Lasa-Zulueta Alberto, Jorquera-Cuevas Cristina. Evaluacion de la situacion asistencial y recomendaciones terapeuticas en el trastorno por deficit de atencion e hiperactividad. [Assessment of healthcare status and therapeutic recommendations concerning attention deficit hyperactivity disorder] Vitoria-Gasteiz: Basque Office for Health

2009 Health Technology Assessment (HTA) Database.

370. Central nervous system stimulants for secondary attention deficit-hyperactivity disorder after paediatric traumatic brain injury: a rationale and protocol for single patient (n-of-1) multiple cross-over trials. Full Text available with Trip Pro

Attention Deficit-Hyperactivity Disorder. There is conflicting evidence on whether treatment with stimulant therapy with medications such as methylphenidate or dexamphetamine will improve the attention and behavior of children with this condition.Single patient trials (n-of-1s or SPTs) evaluate the effect of titrated doses of psychostimulants methylphenidate or dexamphetamine compared to placebo on attention and behavior, in children with TBI and secondary ADHD. The aggregation of multiple SPTs (...) Central nervous system stimulants for secondary attention deficit-hyperactivity disorder after paediatric traumatic brain injury: a rationale and protocol for single patient (n-of-1) multiple cross-over trials. It is estimated that 22,800 children were living with an Acquired Brain Injury (ABI) (0.6% of children aged under 15 years) in Australia during 2003. Many children after a traumatic brain injury will experience difficulties with attention and concentration; a condition termed secondary

2013 BMC pediatrics Controlled trial quality: uncertain

371. Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study. Full Text available with Trip Pro

Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study. The aim of this study was to compare the efficacy and safety of the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant noradrenergic compound atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had previously responded (...) inadequately to methylphenidate (MPH).This 9-week, head-to-head, randomized, double-blind, active-controlled study (SPD489-317; ClinicalTrials.gov NCT01106430) enrolled patients (aged 6-17 years) with at least moderately symptomatic ADHD and an inadequate response to previous MPH therapy. Patients were randomized (1:1) to an optimized daily dose of LDX (30, 50 or 70 mg) or ATX (patients <70 kg, 0.5-1.2 mg/kg with total daily dose not to exceed 1.4 mg/kg; patients ≥70 kg, 40, 80 or 100 mg). The primary

2013 CNS drugs Controlled trial quality: predicted high

372. Long-Term Quality-of-Life and Functioning Comparison of Atomoxetine Versus Other Standard Treatment in Pediatric Attention-Deficit/Hyperactivity Disorder. (Abstract)

Long-Term Quality-of-Life and Functioning Comparison of Atomoxetine Versus Other Standard Treatment in Pediatric Attention-Deficit/Hyperactivity Disorder. Psychopharmacological agents were shown to be important for improving the quality of life (QoL) of patients with attention-deficit/hyperactivity disorder (ADHD). A short-term, 10-week study found atomoxetine (ATX) to be effective in improving QoL of ADHD patients. We compared, for the first time, long-term treatment outcomes of ATX and other (...) early standard therapy (OEST, any pharmacological ADHD treatment except ATX) in QoL and functional impairment in pharmacologically naive children/ adolescents in a randomized, controlled, open-label study at 6 and 12 months. Patients received ATX (0.5-1.8 mg/kg per day) or OEST (mainly methylphenidate). Quality of life and functioning were assessed by the Child Health and Illness Profile-Child Edition, Parent Rating Form and the Weiss Functional Impairment Rating Scale-Parent Report. Three hundred

2013 Journal of Clinical Psychopharmacology

373. Health-Related Quality of Life and Functional Outcomes from a Randomized, Controlled Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Full Text available with Trip Pro

Health-Related Quality of Life and Functional Outcomes from a Randomized, Controlled Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Optimal management of attention deficit hyperactivity disorder (ADHD) aims not only to ameliorate patients' symptoms, but also to improve health-related quality of life (HRQL) and functioning. A pivotal, 7-week, randomized, double-blind, placebo-controlled, phase III study in children and adolescents (...) and a baseline ADHD Rating Scale IV total score ≥28 were randomized (1:1:1) to 7 weeks of double-blind treatment with once-daily LDX, placebo or the reference treatment, osmotic-release oral system methylphenidate (OROS-MPH). Participants' parents (or legally authorized representatives) completed the CHIP-CE:PRF and WFIRS-P questionnaires at baseline, at weeks 4 and 7, and/or at early termination. Endpoint was defined as the last on-treatment visit with valid data (≤30 % missing items). The CHIP-CE:PRF

2013 CNS drugs Controlled trial quality: predicted high

374. Does Methylphenidate Normalize Brain Dysfunction During Fear Learning in Adolescents With Disruptive Behavior Disorders? (Abstract)

Does Methylphenidate Normalize Brain Dysfunction During Fear Learning in Adolescents With Disruptive Behavior Disorders? Conduct disorder (CD) and oppositional defiant disorder (ODD), collectively termed disruptive behavior disorders (DBDs), are a major cause of impairment and suffering in those affected by these conditions and their families and communities. The prevalence of DBDs is estimated at 5-14% in school-aged children,1 and they are costly to society and linked with negative adult (...) outcomes.2 Unfortunately, few effective psychological treatments are available, and there is a lack of evidence-based pharmacological treatments for DBDs.3 The present study by Van Lith et al.4 investigates whether acute methylphenidate administration normalizes low brain activity during fear conditioning in adolescents with DBDs within the context of a randomized controlled trial. While the group of DBD youth who were given placebo showed reduced amygdala activity during fear conditioning relative

2018 Journal of the American Academy of Child and Adolescent Psychiatry Controlled trial quality: uncertain

375. Methylphenidate-placebo: a trial for attention deficit disorders. (Abstract)

Methylphenidate-placebo: a trial for attention deficit disorders. 23981796 2015 06 23 2013 08 28 1092-4221 5 1 2001 Jan-Feb International journal of pharmaceutical compounding Int J Pharm Compd Methylphenidate-placebo: a trial for attention deficit disorders. 21-2 Tenreiro K K The Medicine Shoppe, Canandaigua, New York. eng Journal Article United States Int J Pharm Compd 9706294 1092-4221 2013 8 29 6 0 2001 1 1 0 0 2001 1 1 0 1 ppublish 23981796

2015 International journal of pharmaceutical compounding Controlled trial quality: predicted high

376. Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

: Shire ClinicalTrials.gov Identifier: Other Study ID Numbers: SPD489-405 First Posted: March 13, 2012 Results First Posted: December 11, 2014 Last Update Posted: December 11, 2014 Last Verified: December 2014 Keywords provided by Shire: ADHD Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias (...) : December 11, 2014 Last Update Posted : December 11, 2014 Sponsor: Shire Information provided by (Responsible Party): Shire Study Details Study Description Go to Brief Summary: The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD). Condition or disease Intervention/treatment Phase Attention-deficit/Hyperactivity Disorder Drug: Lisdexamfetamine dimesylate Drug: Methylphenidate Hydrochloride Drug: Placebo

2012 Clinical Trials

377. Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Lisdexamfetamine Dimesylate Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms (...) : March 18, 2015 Last Update Posted : March 18, 2015 Sponsor: Shire Information provided by (Responsible Party): Shire Study Details Study Description Go to Brief Summary: The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD). Condition or disease Intervention/treatment Phase Attention-deficit/Hyperactivity Disorder Drug: Lisdexamfetamine dimesylate Drug: Methylphenidate Hydrochloride Drug: Placebo

2012 Clinical Trials

378. Adult Attention Deficit Hyperactivity Disorder

: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms (...) Summary: A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD). Condition or disease Intervention/treatment Phase Adult Attention Deficit Hyperactivity Disorder Drug: SEP-225289 Drug: Placebo Phase 2 Detailed Description: This is a Phase 2, randomized, double-blind, parallel-group, multicenter, outpatient study evaluating the efficacy and safety of SEP 225289 in adults with ADHD using 2 oral dosages (4 or 8 mg SEP 225289 once daily [QD]) versus placebo over a 4

2012 Clinical Trials

379. Can Task-Switching Training Enhance Executive Control Functioning in Children with Attention Deficit/-Hyperactivity Disorder? Full Text available with Trip Pro

Can Task-Switching Training Enhance Executive Control Functioning in Children with Attention Deficit/-Hyperactivity Disorder? The key cognitive impairments of children with attention deficit/-hyperactivity disorder (ADHD) include executive control functions such as inhibitory control, task-switching, and working memory (WM). In this training study we examined whether task-switching training leads to improvements in these functions. Twenty children with combined type ADHD and stable (...) methylphenidate medication performed a single-task and a task-switching training in a crossover training design. The children were randomly assigned to one of two groups. One group started with the single-task training and then performed the task-switching training and the other group vice versa. The effectiveness of the task-switching training was measured as performance improvements (relative to the single-task training) on a structurally similar but new switching task and on other executive control tasks

2012 Frontiers in human neuroscience Controlled trial quality: uncertain

380. Integrated Diagnosis and Treatment of Adults With Attention-deficit/Hyperactivity Disorder

Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms (...) Arzneimittel Pütter GmbH & Co KG Information provided by (Responsible Party): Medice Arzneimittel Pütter GmbH & Co KG Study Details Study Description Go to Brief Summary: Non-interventional study to gain further information about the therapy progression in routine treatment of adults with attention-deficit/hyperactivity disorder (ADHD). Main focus will be on the improvement of the clinical global impression (CGI) in comparison to the outcome of randomized, controlled studies. Condition or disease Adult

2012 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>